Everolimus: efficacy and safety in cardiac transplantation

Bibliography

• Taylor DO, Stehlik J, Edwards LB, Registry of the International Society for Heart and Lung Transplantation: twenty-sixth official adult heart transplant report – 2009. J Heart Lung Transplant 2009;28(10):1007-22
   PubMed Web of Science ®Google Scholar
• Hiatt WR, Nissen SE. New drug application 21-628, Certican (everolimus), for the proposed indication of prophylaxis of rejection in heart transplantation: report from the Cardiovascular and Renal Drugs Advisory Committee, US Food and Drug Administration, 16 November 2005, Rockville, MD. Circulation 2006;113(10):e394-5
   PubMed Web of Science ®Google Scholar
• Martel RR, Klicius J, Galet S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol 1977;55(1):48-51
   PubMed Web of Science ®Google Scholar
• Brown EJ, Albers MW, Shin TB, A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994;369(6483):756-8
   PubMed Web of Science ®Google Scholar
• Huang S, Bjornsti MA, Houghton PJ. Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther 2003;2(3):222-32
   PubMed Web of Science ®Google Scholar
• Dumont FJ, Kastner C, Iacovone Jr F, Fischer PA. Quantitative and temporal analysis of the cellular interaction of FK-506 and rapamycin in T-lymphocytes. J Pharmacol Exp Ther 1994;268(1):32-41
   PubMed Web of Science ®Google Scholar
• Kahan BD, Wong RL, Carter C, A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients. Transplantation 1999;68(8):1100-6
   PubMed Web of Science ®Google Scholar
• Schuler W, Sedrani R, Cottens S, SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997;64(1):36-42
   PubMed Web of Science ®Google Scholar
• Crowe A, Bruelisauer A, Duerr L, Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. Drug Metab Dispos 1999;27(5):627-32
   PubMed Web of Science ®Google Scholar
• Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004;43(2):83-95
   PubMed Web of Science ®Google Scholar
• Neumayer HH, Paradis K, Korn A, Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients. Br J Clin Pharmacol 1999;48(5):694-703
   PubMed Web of Science ®Google Scholar
• Patel JK, Kobashigawa JA. Everolimus: an immunosuppressive agent in transplantation. Expert Opin Pharmacother 2006;7(10):1347-55
   PubMedGoogle Scholar
• Dingemanse SA, Wong R, Dou L, Multiple-dose pharmacokinetics of the immunosuppressant SDZ RAD in stable renal transplant patients. Transplantation 1998;65(5):138
   PubMedGoogle Scholar
• Kovarik JM, Eisen H, Dorent R, Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. J Heart Lung Transplant 2003;22(10):1117-25
   PubMed Web of Science ®Google Scholar
• Streit F, Armstrong VW, Oellerich M. Rapid liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus, and cyclosporin A in whole blood. Clin Chem 2002;48(6 Pt 1):955-8
   PubMed Web of Science ®Google Scholar
• Jacobsen W, Serkova N, Hausen B, Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD. Transplant Proc 2001;33(1-2):514-15
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Sabia HD, Figueiredo J, Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. Clin Pharmacol Ther 2001;70(5):425-30
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Beyer D, Schmouder RL. Everolimus drug interactions: application of a classification system for clinical decision making. Biopharm Drug Dispos 2006;27(9):421-6
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Curtis JJ, Hricik DE, Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. Transplant Proc 2006;38(10):3456-8
   PubMed Web of Science ®Google Scholar
• Del Moral RG, Olmo A, Osuna A, Role of P-glycoprotein in chronic cyclosporine nephrotoxicity and its relationship to intrarenal angiotensin II deposits. Transplant Proc 1998;30(5):2014-16
   PubMed Web of Science ®Google Scholar
• Podder H, Stepkowski SM, Napoli KL, Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol 2001;12(5):1059-71
   PubMed Web of Science ®Google Scholar
• Gustafsson F, Barth D, Delgado D, The impact of everolimus versus mycophenolate on blood and lymphocyte cyclosporine exposure in heart-transplant recipients. Eur J Clin Pharmacol 2009;65(7):659-65
   PubMed Web of Science ®Google Scholar
• Schuurman HJ, Cottens S, Fuchs S, SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation 1997;64(1):32-5
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Hof A, Baumlin Y, Hof RP. Differential effect of cyclosporine A and SDZ RAD on neointima formation of carotid allografts in apolipoprotein E-deficient mice. Transplantation 2003;76(8):1166-70
   PubMed Web of Science ®Google Scholar
• Eisen HJ, Tuzcu EM, Dorent R, Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003;349(9):847-58
   PubMed Web of Science ®Google Scholar
• Lehmkuhl H, Arizon J, Vigano M, Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients. Transplantation 2009;88(1):115-22
   PubMed Web of Science ®Google Scholar
• Ross H, Pflugfelder P, Haddad H, Reduction of cyclosporine following the introduction of everolimus in maintenance heart transplant recipients: a pilot study. Transpl Int 2010;23(1):31-7
   PubMed Web of Science ®Google Scholar
• Gonzalez-Vilchez F, de Prada JA, Exposito V, Avoidance of calcineurin inhibitors with use of proliferation signal inhibitors in de novo heart transplantation with renal failure. J Heart Lung Transplant 2008;27(10):1135-41
   PubMed Web of Science ®Google Scholar
• Hunt J, Bedanova H, Starling RC, Premature termination of a prospective, open label, randomized, multicenter study of sirolimus to replace calcineurin inhibitors (CNI) in a standard care regimen of CNI, MMF and corticosteroids early after heart transplantation. J Heart Lung Transplant 2007;26(2 Suppl 1):S203
   Web of Science ®Google Scholar
• Kobashigawa JA, Miller LW, Russell SD, Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006;6(6):1377-86
   PubMed Web of Science ®Google Scholar
• Taylor DO, Edwards LB, Aurora P, Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult heart transplant report – 2008. J Heart Lung Transplant 2008;27(9):943-56
   PubMed Web of Science ®Google Scholar
• Taylor DO, Edwards LB, Boucek MM, Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report – 2007. J Heart Lung Transplant 2007;26(8):769-81
   PubMed Web of Science ®Google Scholar
• Mehra MR, Crespo-Leiro MG, Dipchand A, International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy – 2010. J Heart Lung Transplant 2010;29(7):717-27
   PubMed Web of Science ®Google Scholar
• Kobashigawa JA, Tobis JM, Starling RC, Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. J Am Coll Cardiol 2005;45(9):1532-7
   PubMed Web of Science ®Google Scholar
• Mehra MR, Ventura HO, Stapleton DD, Presence of severe intimal thickening by intravascular ultrasonography predicts cardiac events in cardiac allograft vasculopathy. J Heart Lung Transplant 1995;14(4):632-9
   PubMed Web of Science ®Google Scholar
• Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 1995;76(3):412-17
   PubMed Web of Science ®Google Scholar
• Schmid C, Heemann U, Azuma H, Tilney NL. Rapamycin inhibits transplant vasculopathy in long-surviving rat heart allografts. Transplantation 1995;60(7):729-33
   PubMed Web of Science ®Google Scholar
• Eisen H. Long-term cardiovascular risk in transplantation – insights from the use of everolimus in heart transplantation. Nephrol Dial Transplant 2006;21(Suppl 3):iii9-13
   PubMedGoogle Scholar
• Vigano M, Tuzcu M, Benza R, Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis. J Heart Lung Transplant 2007;26(6):584-92
   PubMed Web of Science ®Google Scholar
• Keogh A, Richardson M, Ruygrok P, Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004;110(17):2694-700
   PubMed Web of Science ®Google Scholar
• Mancini D, Pinney S, Burkhoff D, Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003;108(1):48-53
   PubMed Web of Science ®Google Scholar
• Mehra MR, Uber PA. TOR inhibitors and cardiac allograft vasculopathy: is inhibition of intimal thickening an adequate surrogate of benefit? J Heart Lung Transplant 2003;22(5):501-4
   PubMed Web of Science ®Google Scholar
• Kutschka I, Pethig K, Harringer W, Increased plasma homocysteine concentrations accelerate cardiac allograft vasculopathy. J Heart Lung Transplant 2004;23(11):1260-5
   PubMed Web of Science ®Google Scholar
• Farsetti S, Zanazzi M, Caroti L, Lower homocysteine levels in renal transplant recipients treated with everolimus: a possible link with a decreased cardiovascular risk? Transplant Proc 2010;42(4):1381-2
   PubMed Web of Science ®Google Scholar
• Potena L, Grigioni F, Magnani G, Homocysteine-lowering therapy and early progression of transplant vasculopathy: a prospective, randomized, IVUS-based study. Am J Transplant 2005;5(9):2258-64
   PubMed Web of Science ®Google Scholar
• Campistol JM. Minimizing the risk of posttransplant malignancy. Transplant Proc 2008;40(10 Suppl 1):S40-43
   PubMedGoogle Scholar
• Bellmunt J, Szczylik C, Feingold J, Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 2008;19(8):1387-92
   PubMed Web of Science ®Google Scholar
• StatBite: FDA oncology drug product approvals in 2009. J Natl Cancer Inst 2010;102(4):219
   PubMedGoogle Scholar
• Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 2004;77(5):760-2
   PubMed Web of Science ®Google Scholar
• Mohsin N, Budruddin M, Pakkyara A, Complete regression of visceral Kaposi's sarcoma after conversion to sirolimus. Exp Clin Transplant 2005;3(2):366-9
   PubMedGoogle Scholar
• Pranteda G, Feliziani G, Grimaldi M, Sirolimus and regression of Kaposi's sarcoma in immunosuppressed transplant patient. J Eur Acad Dermatol Venereol 2008;22(8):1022-3
   PubMed Web of Science ®Google Scholar
• Kauffman HM, Cherikh WS, Cheng Y, Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005;80(7):883-9
   PubMed Web of Science ®Google Scholar
• Salgo R, Gossmann J, Schofer H, Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant 2010;10(6):1385-93
   PubMed Web of Science ®Google Scholar
• Moro JA, Almenar L, Martinez-Dolz L, Tolerance profile of the proliferation signal inhibitors everolimus and sirolimus in heart transplantation. Transplant Proc 2008;40(9):3034-6
   PubMed Web of Science ®Google Scholar
• Levy G, Schmidli H, Punch J, Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl 2006;12(11):1640-8
   PubMed Web of Science ®Google Scholar
• Zuckermann A, Kobashigawa J, Arizon JM, Incidences of incisional complications after de novo cardiac transplantation in AZA-, MMF- or Everolimus-based regimens: a cross-study analysis on 1008 patients. J Heart Lung Transplant 2009;28(2 Suppl 1):S169
   Web of Science ®Google Scholar
• Rothenburger M, Zuckermann A, Bara C, Recommendations for the use of everolimus (Certican) in heart transplantation: results from the second German-Austrian Certican Consensus Conference. J Heart Lung Transplant 2007;26(4):305-11
   PubMed Web of Science ®Google Scholar
• Kahan BD, Kaplan B, Lorber MI, RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection. Transplantation 2001;71(10):1400-6
   PubMed Web of Science ®Google Scholar
• Delgado J, Manito N, Segovia J, The use of proliferation signal inhibitors in the prevention and treatment of allograft vasculopathy in heart transplantation. Transplant Rev (Orlando) 2009;23(2):69-79
   PubMedGoogle Scholar
• Mueller MA, Beutner F, Teupser D, Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR-/- mice despite severe hypercholesterolemia. Atherosclerosis 2008;198(1):39-48
   PubMed Web of Science ®Google Scholar
• Tenderich G, Fuchs U, Zittermann A, Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients. Clin Transplant 2007;21(4):536-43
   PubMed Web of Science ®Google Scholar
• Pham PT, Pham PC, Danovitch GM, Sirolimus-associated pulmonary toxicity. Transplantation 2004;77(8):1215-20
   PubMed Web of Science ®Google Scholar
• Rehm B, Keller F, Mayer J, Stracke S. Resolution of sirolimus-induced pneumonitis after conversion to everolimus. Transplant Proc 2006;38(3):711-13
   PubMed Web of Science ®Google Scholar
• Bertoni E, Bruschi M, Candiano G, Posttransplant proteinuria associated with everolimus. Transplant Proc 2009;41(4):1216-17
   PubMed Web of Science ®Google Scholar
• Letavernier E, Bruneval P, Mandet C, High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2007;2(2):326-33
   PubMed Web of Science ®Google Scholar
• Gullestad L, Iversen M, Mortensen SA, Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. Transplantation 2010;89(7):864-72
   PubMed Web of Science ®Google Scholar
• Sanchez-Fructuoso AI. Everolimus: an update on the mechanism of action, pharmacokinetics and recent clinical trials. Expert Opin Drug Metab Toxicol 2008;4(6):807-19
   PubMed Web of Science ®Google Scholar
• Potena L, Bianchi I, Magnani G, Cyclosporine lowering with everolimus or mycophenolate to preserve renal function in heart recipients: a randomized study. Transplantation 2010;89(2):263-5
   PubMed Web of Science ®Google Scholar
• Delgado DH, Rao V, Hamel J, Monitoring of cyclosporine 2-hour post-dose levels in heart transplantation: improvement in clinical outcomes. J Heart Lung Transplant 2005;24(9):1343-6
   PubMed Web of Science ®Google Scholar
• Steele GH, Adamkovic AB, Demopoulos LA, Pericardial effusion coincident with sirolimus therapy: a review of Wyeth's safety database. Transplantation 2008;85(4):645-7
   PubMed Web of Science ®Google Scholar
• Bouzas-Mosquera A, Crespo-Leiro MG, Paniagua MJ, Adverse effects of mammalian target of rapamycin inhibitors during the postoperative period after cardiac transplantation. Transplant Proc 2008;40(9):3027-30
   PubMed Web of Science ®Google Scholar
• Truong U, Moon-Grady AJ, Butani L. Cardiac tamponade in a pediatric renal transplant recipient on sirolimus therapy. Pediatr Transplant 2005;9(4):541-4
   PubMed Web of Science ®Google Scholar
• Lehmkuhl H, Ross H, Arizon J, Comparability of pattern of occurrence of pericardial effusions between everolimus- and MMF-based regimen in de novo cardiac transplant recipients. J Heart Lung Transplant 2009;28(2 Suppl 1):S170
   PubMed Web of Science ®Google Scholar
• Puig IMJM, Martinez-Miralles E, Perich X, Reflex sympathetic dystrophy syndrome of the lower limbs in a renal transplant patient treated with tacrolimus. Transplantation 2000;70(1):210-11
   PubMed Web of Science ®Google Scholar
• Grandtnerova B, Spisiakova D, Lepej J, Markova I. Reflex sympathetic dystrophy of the lower limbs after kidney transplantation. Transpl Int 1998;11(Suppl 1):S331-3
   PubMedGoogle Scholar
• Massard C, Fizazi K, Gross-Goupil M, Escudier B. Reflex sympathetic dystrophy in patients with metastatic renal cell carcinoma treated with everolimus. Invest New Drugs 2009. [Epub ahead of print]
   Google Scholar
• Molina MG, Diekmann F, Burgos D, Sympathetic dystrophy associated with sirolimus therapy. Transplantation 2008;85(2):290-2
   PubMed Web of Science ®Google Scholar
• van Gelder T, ter Meulen CG, Hene R, Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation 2003;75(6):788-91
   PubMed Web of Science ®Google Scholar
• De Simone P, Carrai P, Precisi A, Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function. Transpl Int 2009;22(3):279-86
   PubMed Web of Science ®Google Scholar
• De Simone P, Metselaar HJ, Fischer L, Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. Liver Transpl 2009;15(10):1262-9
   PubMed Web of Science ®Google Scholar
• Keogh A, Richardson M, Ruygrok P, Sirolimus vs azathiopine from the time of heart transplantation: 65 month followup for vascular (MACE) and malignant events. J Heart Lung Transplant 2007;26(2 Suppl 1):S231-2
   Web of Science ®Google Scholar